Study of the ability of a new nitric oxide synthase inhibitor INOS1 to selectively protect the normal tissue in the Ehrlich carcinoma radiotherapy model

«Radiation and Risk», 2018, vol. 27, no. 2, pp.37-45

DOI: 10.21870/0131-3878-2018-27-2-37-45


Filimonova M.V. – Head of Lab., D. Sc., Biol. A. Tsyb MRRC, Obninsk. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249036. Tel.: +7 (484) 399-71-36; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Samsonova A.S. – Researcher. A. Tsyb MRRC, Obninsk.
Korneeva T.S. – Researcher. A. Tsyb MRRC, Obninsk.
Shevchenko L.I. – Lead. Researcher., C. Sc., Chem. A. Tsyb MRRC, Obninsk.
Filimonov A.S. – Researcher. A. Tsyb MRRC, Obninsk.


The article presents the ability of the new NOS inhibitor named INOS1, N,S-substituted isothiourea derivative, to selectively protect the normal tissues on the model of Ehrlich solid carcinoma radiotherapy in mice. A single injection of INOS1 (75 mg/kg, ¼ LD16) 30 min before local single-dose (30 Gy) or hypofractionated (20+20 Gy) radiation exposure significantly reduced the radiation alteration of normal tissues and the clinical and morphological severity of acute radiation reactions. The substance did not modify the effects of gamma-radiation on the tumor, grafted on mouse limb, and did not reduce therapeutic effect. Transient suppression of endogenous NO synthesis led to protection of normal tissues exposed to radiation, however, it did not change the radiosensitivity of solid tumor tissues. The results allow authors to consider NOS inhibitors, in particular INOS1, as the promising basis for development of pharmaceuticals for prevention of radiotherapy-induced complications.

Key words
Ehrlich carcinoma, solid form, experimental model, radiotherapy, radiation injuries, complications of radiotherapy, selective protection of normal tissues, nitric oxide, transient suppression of synthesis, inhibitors of nitric oxide synthase.


1. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskij, V.G. Petrova. Moscow, P. Herzen MROI, 2017. 250 p. (In Russian).

2. Radiation medicine. Vol. 2. Radiation damage to humans. Ed.: L.A. Il'in. Moscow, AT, 2001. 432 p. (In Russian).

3. Prasanna P.G., Stone H.B., Wong R.S., Capala J., Bernhard E.J., Vikram B., Coleman C.N. Normal tissue protection for improving radiotherapy: Where are the gaps? Transl. Cancer Res., 2012, vol. 1, no. 1, pp. 35-48.

4. Kim J.H., Jenrow K.A., Brown S.L. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat. Oncol. J., 2014, vol. 32, no. 3, pp. 103-115.

5. Filimonova M.V., Shevchenko L.I., Trofimova T.P., Makarchuk V.M., Shevchuk A.S., Lushnikova G.A. On the mechanism of radioprotective effect of NO-synthase inhibitors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2014, vol. 54, no. 5, pp. 500-506. (In Russian).

6. Filimonova M.V., Shevchenko L.I., Makarchuk V.M., Chesnakova E.A., Izmest'eva O.S., Korneeva T.S., Filimonov A.S. Radioprotective properties of NO-synthase inhibitor T1023: I. Indicators of radioprotective activity and interaction with other radioprotectors. Radiatsionnaya biologiya.Radioekologiya – Radiation Biology. Radioecology, 2015, vol. 55, no. 3, pp. 250-259. (In Russian).

7. Filimonova M.V., Ul'janenko S.E., Shevchenko L.I., Kuznecova M.N., Makarchuk V.M., Chesnakova E.A., Samsonova A.S., Filimonov A.S. Radioprotective properties of NO-synthase inhibitor T1023: II. The ability for selective protection of normal tissue during radiotherapy of tumors. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2015, vol. 55, no. 3, pp. 260-266. (In Russian).

Full-text article (in Russian)